Carfizome 60 Carfilzomib for Injection 60mg/Vial In Pakistan

Carfizome 60 contains Carfilzomib 60 mg, a proteasome inhibitor used in the treatment of multiple myeloma, a type of blood cancer. It is supplied as a powder for solution and is administered by intravenous infusion under the supervision of a qualified healthcare professional.

Carfizome 60 Composition

• Active Ingredient: Carfilzomib
• Strength: 60 mg per vial
• Dosage Form: Powder for solution for injection/infusion
• Route of Administration: Intravenous (IV)
• Therapeutic Class: Proteasome inhibitor
• Primary Use: Treatment of multiple myeloma

What Is Carfizome 60 Used For?

Carfizome 60 is used as part of combination treatment for multiple myeloma in patients who have received previous treatments. Carfilzomib works by inhibiting proteasomes, cellular structures responsible for breaking down proteins. Blocking these structures can cause abnormal myeloma cells to stop growing and eventually die.

The exact treatment combination and duration depend on the patient's previous therapy, overall health, and the prescribing oncologist's treatment plan.

How Does Carfilzomib Work?

Carfilzomib is an irreversible proteasome inhibitor. It interferes with the normal breakdown of proteins inside cancer cells. Multiple myeloma cells are particularly dependent on this protein-processing system, so proteasome inhibition can lead to accumulation of unwanted proteins and cancer-cell death.

Carfizome 60 Administration

Carfizome 60 is given intravenously (IV) by a healthcare professional. The dose and infusion schedule are individualized according to the treatment regimen, body surface area or body weight, kidney function, previous therapies, and the patient's response to treatment.

Patients should not self-administer Carfizome 60. It should be prepared and administered by trained medical personnel in an appropriate clinical setting.

Possible Side Effects

Like other anticancer medicines, Carfilzomib may cause side effects. Possible effects include:

• Fatigue and weakness
• Nausea or vomiting
• Diarrhea
• Fever
• Headache
• Shortness of breath
• Decreased appetite
• Anemia
• Low platelet or white blood cell counts
• Increased blood pressure
• Infusion-related reactions

Carfilzomib can also cause serious adverse reactions, including cardiac complications, kidney problems, breathing difficulties, infections, and blood-clotting complications. Patients receiving treatment should be closely monitored by their healthcare team.

Precautions

Before treatment with Carfizome 60, inform the doctor about any history of:

• Heart disease or heart failure
• High blood pressure
• Kidney problems
• Liver problems
• Breathing or lung problems
• Previous blood clots
• Allergies to medicines
• Current medications and cancer treatments

Blood tests and other medical assessments may be required before and during treatment to monitor blood counts, kidney function, liver function, and other relevant parameters.

Storage and Handling

Carfizome 60 should be stored and handled according to the manufacturer's instructions and applicable pharmaceutical storage requirements. The product should be prepared for administration only by qualified healthcare professionals.

Carfizome 60 in Pakistan

Carfizome 60 Carfilzomib for Injection 60mg/vial may be required by patients undergoing specialist treatment for multiple myeloma in Pakistan. Availability can vary between cities and pharmacies. It should be obtained through a licensed pharmaceutical supplier or pharmacy and used only under the supervision of an oncologist.

Available in Major Cities of Pakistan

Carfizome 60 may be available for patients in:

Lahore, Karachi, Islamabad, Rawalpindi, Multan, Faisalabad, Peshawar, Gujranwala, Hyderabad, Bahawalpur, Sialkot, Sukkur, Larkana and other major cities of Pakistan.

Buy Carfizome 60 in Pakistan

If you are looking for Carfizome 60 Carfilzomib 60mg/vial in Pakistan, availability and supply should be confirmed before ordering. Patients should provide a valid prescription and consult their oncologist regarding the appropriate treatment regimen.